CN104797271B - 雄激素合成调节剂 - Google Patents

雄激素合成调节剂 Download PDF

Info

Publication number
CN104797271B
CN104797271B CN201380054623.0A CN201380054623A CN104797271B CN 104797271 B CN104797271 B CN 104797271B CN 201380054623 A CN201380054623 A CN 201380054623A CN 104797271 B CN104797271 B CN 104797271B
Authority
CN
China
Prior art keywords
day
acid
hormone
disclosed
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380054623.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104797271A (zh
Inventor
苏珊妮·简·迪利
格雷戈里·艾伦·斯托洛弗
保罗·克里斯多佛·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tangent Reprofiling Ltd
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of CN104797271A publication Critical patent/CN104797271A/zh
Application granted granted Critical
Publication of CN104797271B publication Critical patent/CN104797271B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201380054623.0A 2012-09-26 2013-09-26 雄激素合成调节剂 Active CN104797271B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705790P 2012-09-26 2012-09-26
US61/705,790 2012-09-26
US201361871662P 2013-08-29 2013-08-29
US61/871,662 2013-08-29
PCT/EP2013/070106 WO2014049071A1 (en) 2012-09-26 2013-09-26 Modulators of androgen synthesis

Publications (2)

Publication Number Publication Date
CN104797271A CN104797271A (zh) 2015-07-22
CN104797271B true CN104797271B (zh) 2020-03-06

Family

ID=49293617

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380054623.0A Active CN104797271B (zh) 2012-09-26 2013-09-26 雄激素合成调节剂

Country Status (14)

Country Link
US (4) US9072743B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900270B1 (cg-RX-API-DMAC7.html)
JP (2) JP6434410B2 (cg-RX-API-DMAC7.html)
CN (1) CN104797271B (cg-RX-API-DMAC7.html)
AU (2) AU2013322612B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015006727B1 (cg-RX-API-DMAC7.html)
CA (1) CA2886132C (cg-RX-API-DMAC7.html)
ES (1) ES2734554T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211868A1 (cg-RX-API-DMAC7.html)
IL (2) IL237892B (cg-RX-API-DMAC7.html)
MX (1) MX367782B (cg-RX-API-DMAC7.html)
NZ (1) NZ706067A (cg-RX-API-DMAC7.html)
PL (1) PL2900270T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014049071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) * 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034129A2 (en) * 2006-09-15 2008-03-20 Cornell Research Foundation Inc. Treatment of cancer or obesity with conjugated linoleic acids

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
JPH05502217A (ja) * 1989-08-21 1993-04-22 ベス イスラエル ホスピタル アソシエーション セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6319950B1 (en) 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
JPH1192343A (ja) * 1997-09-22 1999-04-06 Shiseido Co Ltd 毛髪成長期延長剤
JPH11209279A (ja) * 1998-01-05 1999-08-03 Natural Ltd As 体重減少および肥満処置の方法
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
EP1480629A1 (en) * 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2005066196A1 (en) 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
EP1890700A2 (en) * 2005-05-31 2008-02-27 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
AR070313A1 (es) 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
DK2280928T3 (en) * 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
CN101366705B (zh) * 2008-09-28 2010-09-08 浙江大学 利培酮透皮吸收贴片
US8420077B2 (en) 2009-04-20 2013-04-16 Allergan, Inc. Silk fibroin hydrogels and uses thereof
WO2012026663A1 (ko) * 2010-08-25 2012-03-01 이화여자대학교 산학협력단 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
EP2907504B1 (en) * 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2014027973A1 (en) * 2012-08-14 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Paliperidone oral solution
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
AU2015257594A1 (en) 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034129A2 (en) * 2006-09-15 2008-03-20 Cornell Research Foundation Inc. Treatment of cancer or obesity with conjugated linoleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance Protein";Jun-Sheng Wang,et al.;《Basic & Clinical Pharmacology & Toxicology》;20081231;第103卷(第4期);第336-341页 *

Also Published As

Publication number Publication date
BR112015006727A2 (pt) 2017-07-04
IL237892A0 (en) 2015-05-31
AU2017221819A1 (en) 2017-09-21
CA2886132C (en) 2023-03-21
US20180064713A1 (en) 2018-03-08
AU2013322612A2 (en) 2015-04-09
CA2886132A1 (en) 2014-04-03
NZ706067A (en) 2016-07-29
US9585887B2 (en) 2017-03-07
US20150258095A1 (en) 2015-09-17
JP2019052159A (ja) 2019-04-04
AU2013322612B2 (en) 2017-06-01
BR112015006727A8 (pt) 2019-08-27
WO2014049071A1 (en) 2014-04-03
IL266446A (en) 2019-06-30
JP6734346B2 (ja) 2020-08-05
US9808462B2 (en) 2017-11-07
JP2015532920A (ja) 2015-11-16
AU2013322612A1 (en) 2015-04-09
CN104797271A (zh) 2015-07-22
EP2900270B1 (en) 2019-03-06
AU2017221819B2 (en) 2019-05-02
EP2900270A1 (en) 2015-08-05
JP6434410B2 (ja) 2018-12-05
MX367782B (es) 2019-09-04
BR112015006727B1 (pt) 2022-08-16
ES2734554T3 (es) 2019-12-10
PL2900270T3 (pl) 2019-09-30
US9072743B2 (en) 2015-07-07
US20170189407A1 (en) 2017-07-06
US20140088120A1 (en) 2014-03-27
IL237892B (en) 2019-05-30
HK1211868A1 (en) 2016-06-03
MX2015003899A (es) 2015-11-25

Similar Documents

Publication Publication Date Title
US9808462B2 (en) Modulators of androgen synthesis
US10111877B2 (en) Modulators of androgen synthesis
CN106456644B (zh) 雄激素合成调节剂
US20230338314A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
PT2164844E (pt) Derivados de pirimidinil-piridazinona
JP2017514816A5 (cg-RX-API-DMAC7.html)
JP2024537139A (ja) KRAS G12D阻害剤とPI3Ka阻害剤との組み合わせ及び関連する治療方法
KR20160124909A (ko) 에스트로겐 수용체 조절제를 함유하는 치료 조합물
TW202337451A (zh) Ntsr1靶向放射性藥物及dna損傷反應抑制劑之組合療法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant